Tesamorelin desensitization: what the evidence actually shows

What did @chandavisand actually say?

The creator defends a personal choice to cycle tesamorelin five days on, two days off, rather than dosing seven days a week. They explicitly say "there's no study saying one is better than the other" and frame the break as a possible "tolerance break" for receptors. Critically, they own the uncertainty: "That might not matter. I don't know." That kind of hedging is actually rare in peptide TikTok, and it matters when you're evaluating how much weight to put on what they said.

The claim is not that five-on/two-off is superior. It is that no evidence clearly favors seven-day dosing, and that a receptor break is a plausible rationale. Those are two separate claims worth pulling apart.

Does the science back this up?

On the narrow factual question, the creator is mostly right, but the reasoning behind the cycling rationale is shakier than they let on. The published tesamorelin trials, including the pivotal IGLOO studies reviewed by Falutz et al. (2010, New England Journal of Medicine), used daily dosing continuously. There is no published randomized controlled trial directly comparing five-on/two-off to seven-day dosing for tesamorelin specifically.

The receptor desensitization logic draws loosely from what we know about growth hormone secretagogue receptor (GHS-R) biology. Continuous GHRH agonism can blunt pituitary responsiveness over time, a phenomenon observed in older analog research (Thorner et al., 1997, Journal of Clinical Endocrinology and Metabolism). However, whether a two-day weekly break is sufficient to meaningfully reset GHS-R sensitivity, or whether it matters clinically at all for tesamorelin, has not been tested in a published trial. The mechanism sounds plausible. The specific protocol is extrapolation.

What did they get wrong (or right)?

Credit where it is due: the creator does not oversell this. They say it is a personal preference and explicitly disclaim certainty. That epistemic honesty is not nothing in a space full of confident-sounding nonsense.

What they get wrong, or at least understate, is that the "no study saying one is better" framing cuts both ways. The absence of evidence for seven-day superiority is not the same as evidence that cycling is safe or effective. The FDA-approved dosing regimen for tesamorelin (Egrifta) is daily subcutaneous injection. When you deviate from that, you are operating outside the studied protocol, and the burden of proof sits with the deviation, not with the standard approach.

The receptor desensitization argument also borrows from GnRH and other pulsatile hormone axis research where cycling clearly matters (Conn and Crowley, 1994, Annual Review of Medicine). Applying that logic to tesamorelin is not unreasonable, but it is an analogy, not a data point. Presenting it as a coherent rationale without that caveat could give viewers more confidence in the protocol than the evidence supports.

What should you actually know?

Tesamorelin is a GHRH analog, meaning it stimulates the pituitary to produce growth hormone rather than replacing it directly. This pulsatile mechanism is actually one reason the receptor saturation concern has some biological plausibility. But plausibility is not proof.

If you are using tesamorelin under medical supervision, your prescriber should be guiding your dosing protocol based on your IGF-1 levels and clinical response, not TikTok comment sections. IGF-1 monitoring is the standard tool for assessing whether the dose is working and whether you are overshooting into a range associated with adverse effects (Clemmons, 2011, Growth Hormone and IGF Research).

The bigger issue here is not five-on/two-off versus daily. It is that tesamorelin is a regulated compound with a specific approved indication, and the peptide optimization space often treats it like a fitness supplement with no meaningful stakes. There are real side effects, including fluid retention, glucose dysregulation, and injection site reactions, documented in the clinical trials. The dosing schedule is one variable. Regular lab monitoring is not optional if you want to use this responsibly.

FormBlends verdict

The creator's core claim, that no study definitively favors seven-day over five-on/two-off dosing, is accurate as far as published literature goes. The receptor tolerance rationale is biologically plausible but unproven for this specific compound and protocol. What saves this video from being misinformation is the creator's own uncertainty. They said "I don't know" before most commenters on peptide TikTok would. That is worth acknowledging, even if the video should have been clearer that the approved protocol is daily dosing and that deviations require medical oversight, not community consensus.